The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Hinsley, S, Walker, K, Sherratt, D et al. (13 more authors) (2020) The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 21 (1). 826. 826-.

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s), 2020. This is an open access article under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/)
Dates:
  • Accepted: 12 September 2020
  • Published (online): 2 October 2020
  • Published: 2 October 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 16 Oct 2020 12:12
Last Modified: 16 Oct 2020 12:12
Status: Published
Publisher: Springer Science and Business Media LLC
Identification Number: https://doi.org/10.1186/s13063-020-04739-8
Related URLs:

Share / Export

Statistics